38923-57-8Relevant articles and documents
Process for the alkylation of active methylene compounds
-
Paragraph 0157-0162, (2017/02/24)
The invention discloses an alkylation method of an active methylene compound. The method comprises the following steps: A, adding the active methylene compound to an inorganic alkali-first polar organic solvent mixing system to form a to-be-reacted mixture; B, adding an alkylating agent to the to-be-reacted mixture, filtering after reacting to obtain filtrate, and removing a solvent in the filtrate to obtain the alkylated active methylene compound. According to the method, the inorganic alkali is adopted as a proton abstraction reagent of the active methylene compound, so that the removal effect on alpha-hydrogen in the active methylene compound can be ensured, the alkylation reaction of the active methylene compound can be carried out under a mild condition, and the reaction safety is improved. Meanwhile, the inorganic alkali is low in price, so that the production cost of the alkylation reaction is reduced.
PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
-
Page/Page column 177-178, (2012/10/07)
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
-
, (2012/04/23)
The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.